BRIEF — Pharming Presents Positive Phase II Topline Data For Leniolisib
Oct 14 (Reuters) — Pharming Group N.V.: Presents Positive Phase Ii Topline Data For Leniolisib In Genetic Pids With Immune Dysregulation At Esid 2026 Leniolisib Well-tolerated With Benefits In Immune Dysregulation Measures Mean Spleen Volume Reduction Of 26.4% In Phase Ii Leniolisib Trial Improvement In Liver Stiffness